Pierre Colin
Research Subjects
Pierre Colin has a total of 209 co-authors. Here are the top co-authors by number of shared publications:
- Nacim Betrouni
Univ. Lille, INSERM, UMR1172 -Lille Neuroscience & Cognition, F-59000 Lille, France
6 shared publications - Serge Mordon
Hemerion Therapeutics, 59650 Villeneuve d’Ascq, France
6 shared publications - Arnauld Villers
Department of Urology, Lille University Hospital, 59000 Lille, France
5 shared publications - Thomas Seisen
Academic Department of Urology, Pitié-Salpêtrière Hospital, APHP, 47-83 boulevard de l'hopital, 75013, Paris, France
5 shared publications Adil Ouzzane
Claude Huriez University Hospital, CHRU Lille
4 shared publicationsM. Roupret
4 shared publications
Latest Publications
- Open Access
The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival
(1) Background—The five-year overall survival (OS) of muscle-invasive bladder cancer (MIBC) with neoadjuvant chemotherapy and cystectomy is around 50%. There is no validated biomarker to guide the treatment decision. We investigated whether the Immunoscore (IS) could predict the pathologic response to neoadjuvant chemotherapy and survival outcomes. (2) Methods—This retrospective study evaluated the IS in 117 patients treated using neoadjuvant chemotherapy for localized MIBC from six centers (France and Greece). Pre-treatment tumor samples were immunostained for CD3+ and CD8+ T cells and quantified to determine the IS. The results were associated with the response to neoadjuvant chemotherapy, time to recurrence (TTR), and OS. (3) Results—Low (IS-0), intermediate (IS-1–2), and high (IS-3–4) ISs were observed in 36.5, 43.7, and 19.8% of the cohort, respectively. IS was positively associated with a pathologic complete response (pCR; p-value = 0.0096). A high IS was found in 35.7% of patients with a pCR, whereas it was found in 11.3% of patients without a pCR. A low IS was observed in 48.4% of patients with no pCR and in 21.4% of patients with a pCR. Low-, intermediate-, and high-IS patients had five-year recurrence-free rates of 37.2%, 36.5%, and 72.6%, respectively. In the multivariable analysis, a high IS was associated with a prolonged TTR (high vs. low: p = 0.0134) and OS (high vs. low: p = 0.011). (4) Conclusions—This study showed the significant prognostic and predictive roles of IS regarding localized MIBC.
Open AccessThe Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival
(1) Background—The five-year overall survival (OS) of muscle-invasive bladder cancer (MIBC) with neoadjuvant chemotherapy and cystectomy is around 50%. There is no validated biomarker to guide the treatment decision. We investigated whether the Immunoscore (IS) could predict the pathologic response to neoadjuvant chemotherapy and survival outcomes. (2) Methods—This retrospective study evaluated the IS in 117 patients treated using neoadjuvant chemotherapy for localized MIBC from six centers (France and Greece). Pre-treatment tumor samples were immunostained for CD3+ and CD8+ T cells and quantified to determine the IS. The results were associated with the response to neoadjuvant chemotherapy, time to recurrence (TTR), and OS. (3) Results—Low (IS-0), intermediate (IS-1–2), and high (IS-3–4) ISs were observed in 36.5, 43.7, and 19.8% of the cohort, respectively. IS was positively associated with a pathologic complete response (pCR; p-value = 0.0096). A high IS was found in 35.7% of patients with a pCR, whereas it was found in 11.3% of patients without a pCR. A low IS was observed in 48.4% of patients with no pCR and in 21.4% of patients with a pCR. Low-, intermediate-, and high-IS patients had five-year recurrence-free rates of 37.2%, 36.5%, and 72.6%, respectively. In the multivariable analysis, a high IS was associated with a prolonged TTR (high vs. low: p = 0.0134) and OS (high vs. low: p = 0.011). (4) Conclusions—This study showed the significant prognostic and predictive roles of IS regarding localized MIBC.
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e2021-e2022
Trends of lymphadenectomy in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: The impact of surgical technique
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e2021-e2022
Trends of lymphadenectomy in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: The impact of surgical technique
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e2033-e2037
Robotic radical nephroureterectomy is associated with poorer oncological outcomes than open and laparoscopic radical nephroureterectomy
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e2033-e2037
Robotic radical nephroureterectomy is associated with poorer oncological outcomes than open and laparoscopic radical nephroureterectomy
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e2017-e2018
Comparing oncological outcomes of laparoscopic versus open nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity match analysis
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e2017-e2018
Comparing oncological outcomes of laparoscopic versus open nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity match analysis
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e863-e864
Added value of pre-biopsy prostate multiparametric MRI in biopsy-naïve patients: Preliminary results of the MRI-FIRST trial
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e863-e864
Added value of pre-biopsy prostate multiparametric MRI in biopsy-naïve patients: Preliminary results of the MRI-FIRST trial
- 1 April 2014
- Published by Elsevier in European Urology Supplements
- Vol. 13 (1) , e14-e14a
14 Radical nephroureterectomy versus endoscopic procedures for the treatment of upper urinary tract urothelial carcinoma: A meta-analysis of comparative studies
- 1 April 2014
- Published by Elsevier in European Urology Supplements
- Vol. 13 (1) , e14-e14a
14 Radical nephroureterectomy versus endoscopic procedures for the treatment of upper urinary tract urothelial carcinoma: A meta-analysis of comparative studies
- 29 June 2013
- Published by Springer Nature in World Journal of Urology
- Vol. 32 (2) , 507-512
Risk stratification of metastatic recurrence in invasive upper urinary tract carcinoma after radical nephroureterectomy without lymphadenectomy
- 29 June 2013
- Published by Springer Nature in World Journal of Urology
- Vol. 32 (2) , 507-512
Risk stratification of metastatic recurrence in invasive upper urinary tract carcinoma after radical nephroureterectomy without lymphadenectomy
- Open Access
- 12 April 2013
- Published by Wiley in BJU International
- Vol. 111 (8) , 1199-1207
Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy
Objectives: To assess the impact of lymphovascular invasion ( LVI ) on upper urinary tract urothelial carcinomas ( UTUCs ) in a multicentre study on cancer‐specific survival ( CSS ), recurrence‐free survival and metastasis‐free survival ( MFS ). To show the negative impact of LVI for patients with pN0 /x disease and to stratify these patients into risk groups for metastatic relapse. Patients and Methods: A multicentre retrospective study was performed on patients who underwent radical nephroureterectomy between 1995 and 2010. LVI status was evaluated as a prognostic factor for survival using univariate and multivariate C ox regression analysis. Results: Overall, 551 patients were included and were divided into two groups: those without LVI ( LVI −), n = 388 and those with LVI ( LVI +), n = 163. LVI + status was associated with high stage and grade UTUC and lymph node metastasis ( P < 0.001). The 5‐year CSS and MFS rates were significantly worse in the LVI + group than in LVI − group (52.2 vs 84.5%, P < 0.001 and 43.8 vs 82.7%, P < 0.001, respectively). In multivariate analysis, LVI + status was an independent prognostic factor for CSS and MFS ( P = 0.04 and P < 0.001). These findings were confirmed for the pN0 /x patient subgroup ( n = 504, P < 0.001). In the pN0 /x patient subgroup, we described a prognostic tool for MFS based on independent factors that permitted us to stratify patients into groups of high, intermediate or low risk of metastasis relapse. Conclusions: The presence of LVI was a strong predictor of a poor outcome for UTUC . When a lymphadenectomy has not been achieved, the report of LVI status is crucial to identfiy those patients at higher risk for metastatic relapse.
- 12 April 2013
- Published by Wiley in BJU International
- Vol. 111 (8) , 1199-1207
Open AccessImpact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy
Objectives: To assess the impact of lymphovascular invasion ( LVI ) on upper urinary tract urothelial carcinomas ( UTUCs ) in a multicentre study on cancer‐specific survival ( CSS ), recurrence‐free survival and metastasis‐free survival ( MFS ). To show the negative impact of LVI for patients with pN0 /x disease and to stratify these patients into risk groups for metastatic relapse. Patients and Methods: A multicentre retrospective study was performed on patients who underwent radical nephroureterectomy between 1995 and 2010. LVI status was evaluated as a prognostic factor for survival using univariate and multivariate C ox regression analysis. Results: Overall, 551 patients were included and were divided into two groups: those without LVI ( LVI −), n = 388 and those with LVI ( LVI +), n = 163. LVI + status was associated with high stage and grade UTUC and lymph node metastasis ( P < 0.001). The 5‐year CSS and MFS rates were significantly worse in the LVI + group than in LVI − group (52.2 vs 84.5%, P < 0.001 and 43.8 vs 82.7%, P < 0.001, respectively). In multivariate analysis, LVI + status was an independent prognostic factor for CSS and MFS ( P = 0.04 and P < 0.001). These findings were confirmed for the pN0 /x patient subgroup ( n = 504, P < 0.001). In the pN0 /x patient subgroup, we described a prognostic tool for MFS based on independent factors that permitted us to stratify patients into groups of high, intermediate or low risk of metastasis relapse. Conclusions: The presence of LVI was a strong predictor of a poor outcome for UTUC . When a lymphadenectomy has not been achieved, the report of LVI status is crucial to identfiy those patients at higher risk for metastatic relapse.